Latest news with #Smith+Nephew
Yahoo
03-07-2025
- Business
- Yahoo
$7.80 Billion by 2030: Why Single-Use Surgical Instruments Are Reshaping Global Surgery
DELRAY BEACH, Fla., July 3, 2025 /PRNewswire/ -- What's fueling the shift from sterilization to scalability? The global single-use surgical instruments market, valued at US$5.60 billion in 2024, stood at US$5.92 billion in 2025 and is projected to advance at a resilient CAGR of 5.7% from 2025 to 2030, culminating in a forecasted valuation of US$7.80 billion by the end of the period. This growth is being driven by the rise of minimally invasive, short-stay, and outpatient surgeries—procedures that demand efficiency, sterility, and speed. Disposable tools are no longer just convenient—they are mission-critical assets for modern surgical care. Download PDF Brochure: Why are single-use surgical instruments becoming a new clinical benchmark? In high-risk surgeries such as general, ophthalmic, dental, and cardiovascular procedures, hospitals are under pressure to minimize infection, reduce turnaround time, and ensure tool readiness. Single-use instruments meet these demands with precise, sterile, ready-to-use tools that support faster recovery, reduce complications, and align with evolving patient care models like same-day discharge and ambulatory surgery. What challenges do single-use surgical instruments solve? They solve the pressing issues of cross-contamination, procedural inefficiency, and high sterilization costs. In underserved or rural healthcare facilities, limited access to reprocessing systems makes reusable tools a risk. Single-use surgical instruments eliminate these barriers, delivering hygienic, high-performance solutions that simplify workflows and improve patient safety. Where is adoption accelerating the fastest? Emerging markets such as India, Asia Pacific, Latin America, and sub-Saharan Africa are rapidly expanding healthcare infrastructure. With India conducting over 30 million surgeries annually, the demand for disposable, low-maintenance instruments are surging. These regions offer cost-effective pathways to scale sterile surgical care across both urban and rural settings. Request Sample Pages : Who are the key leaders—and how are they gaining ground? Market frontrunners include Ethicon, Medtronic, and BD, backed by global reach and deep R&D strength. Other major players like Smith+Nephew, STERIS, and B. Braun are expanding through acquisitions, strategic partnerships, and global training centers—including Smith+Nephew's surgical innovation center in Munich and STERIS's acquisition of BD's instrumentation business. What's the biggest challenge—and how do we overcome it? High cost and environmental sustainability are key hurdles. Smaller hospitals often rely on reusable tools due to budget limits. Simultaneously, increased medical waste is drawing scrutiny. Forward-thinking suppliers will win by delivering cost-efficient, eco-conscious single-use solutions backed by clear clinical and operational ROI. What should healthcare leaders be asking now?Not "Should we switch to disposables?"—but rather:• How can we cut infection risks without compromising efficiency?• Where can we reduce operational overhead from sterilization bottlenecks?• How do single-use instruments fit into our outpatient care strategy?• Which partners best align with our compliance, safety, and growth goals? Final Thought: In Sterility, There Is Strategy. In Simplicity, There Is global shift toward safe, efficient, and rapid-turnaround surgery is here. Single-use surgical instruments deliver the hygiene, performance, and reliability modern care demands. Facilities that embrace this model will lead on patient outcomes, cost control, and regulatory compliance. In the new era of surgery—precision, performance, and protection begin with single-use. For more information, Inquire Now! Related Reports: Surgical Sutures Market Wound Care Market Biosurgery Market Knee Replacement Surgery Market Surgical Suction Instruments Market Get access to the latest updates on Top Companies in Single-use Surgical Instruments and Single-use Surgical Instruments Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC. 1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Print
03-07-2025
- Health
- The Print
India's 1st robot-assisted cementless knee replacement at Delhi hospital. What sets the procedure apart
Led by Dr Sujoy Bhattacharjee, chairman of the Max Institute of Robotic Joint Replacement, the surgical team opted for a cementless implant, using the CUVIS robotic system for precise alignment and placement of the implant, tailored to the patient's unique anatomy. 'We use markers and trackers to guide the robot during surgery,' Dr Bhattacharjee told media persons Wednesday. The procedure was performed Monday on a 54-year-old patient from Jharkhand suffering from advanced osteoarthritis and severe knee deformities such as bow-leggedness (varus) and restricted knee extension (flexion). New Delhi: Doctors at the Max Super Speciality Hospital in Delhi's Saket have successfully performed the country's first robot-assisted cementless medial pivot knee replacement, marking a major milestone for joint replacement surgery in India. He said that the goal was not just to replace the knee, but to preserve key structures, especially ligaments, including the posterior cruciate ligament, which plays a critical role in knee stability. A robot-assisted cementless medial pivot knee replacement is an advanced surgical technique that combines precision robotics with an implant design that closely replicates the natural movement of the human knee. Unlike traditional knee replacements that use bone cement to fix the implant, the cementless approach enables the patient's natural bone to grow into the implant, enhancing long-term stability and durability. This combination of robotic precision, cementless fixation and anatomical design results in faster recovery, reduced post-operative pain, and improved overall joint function. Dr Bhattacharjee demonstrated how a normal knee consists of three bones working in coordination—the upper, lower and the kneecap—with movement supported by two main ligaments, the anterior and posterior cruciate. In traditional surgeries, the implant is fixed using bone cement, but in this case, they opted for a cementless implant made of titanium, which allows the bone to grow naturally into the surface. Using real-time data from the Optical Tracking System (OTS), the surgical team monitored the 'gap', the space between the implant and bone, at every angle of knee movement, whether sitting or standing. Dr Bhattacharjee explained that they first place a trial implant to assess alignment and mobility, and proceed with the final implant only after confirming that the gaps remain consistent at all angles. 'That's the beauty of robotic surgery; it's precise, evidence-based and fully trackable,' he said, noting that post-operative mobility in the patient's leg was excellent, with a smooth range of motion. Doctors at Max claimed that theirs was the world's first robot-assisted cementless medial pivot knee replacement. However, in June 2022, Smith+Nephew, a global medical technology company, had already performed what was widely reported as the world's first robot-assisted cement-free total knee replacement. On 30 June that year, Dr Cyna Khalily in Louisville, Kentucky, used the LEGION CONCELOC cementless implant in combination with the CORI surgical robot for the procedure. The surgery eliminated the need for bone cement and employed a handheld robotic tool to precisely prepare the bone. Dr Bhattacharya clarified that the distinction lay in the type of robotic system used. The CORI system in the 2022 surgery, he said, was a passive robot controlled and guided manually by the surgeon. In contrast, the system used in the Max procedure was an active robot, capable of independently executing pre-programmed movements, which, according to him, sets it apart as a global first of its kind. Also Read: In battle for Indian anti-obesity market, Eli Lilly's pre-filled pen on one side, Novo Nordisk's on other Faster recovery, less chance of loosening Highlighting the benefits of a non-cemented implant, Dr Bhattacharjee said the procedure is quicker because it eliminates the 12-15 minutes usually needed for cement to set. 'In bilateral knee replacements, this alone can save nearly 25 minutes.' The implant bonds directly with the bone, without any cement in between, leading to stronger, more natural integration and better long-term outcomes. He noted that while cement can sometimes compensate for small surgical errors, cementless implants leave no room for error, making surgical expertise crucial. The added benefits include a lower risk of infection, reduced hospital stay as well as faster and smoother recovery due to the biological bonding process. Dr Ankush Sharma, clinical associate and part of Dr Bhattacharjee's team, explained that cementless implants are designed with microscopic pores. 'The patient's bone grows into these pores, locking the implant in place naturally,' he said. In contrast, cemented implants rely on an artificial bond. Cement sticks to both the implant and the bone, but the bone doesn't grow into it. 'Over 10 to 20 years, that cement bond can weaken and lead to loosening,' said Dr Sharma. But with a cementless implant, once bone growth secures it, the chances of loosening are drastically reduced. (Edited by Sugita Katyal) Also Read: Govt considers low-dose emicizumab for haemophilia, trial finds it more effective than existing treatment
Business Upturn
29-06-2025
- Business
- Business Upturn
Global Sports Medicine leader Smith+Nephew to sponsor select players competing at Wimbledon, highlighting advanced solutions for joint repair
By GlobeNewswire Published on June 29, 2025, 16:00 IST Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces it will once again support select players during high profile matches at The Championships, Wimbledon in 2025. The world's oldest and most prestigious tennis tournament serves as a perfect backdrop to showcase Smith+Nephew's purpose of 'Life Unlimited' – making a difference in patients' lives through the excellence of a diverse Sports Medicine product portfolio and the application of new technologies. Tennis is a high-impact sport that places great stress on various areas of the body – especially joints – often resulting in injury. Some of the latest technologies and solutions from Smith+Nephew for joint repair include: REGENETEN◊ Bioinductive Implant: With more than 150,000 procedures1 completed globally since its introduction in 2014, the REGENETEN Bioinductive Implant has had a transformative impact amongst those having surgery for rotator cuff tears; demonstrating lower re-tear rates than reported compared to conventional techniques.2-6 Backed by level one clinical evidence,2 the collagen-based implant supports the body's natural healing response to facilitate the formation of new tendon-like tissue to biologically augment the existing tendon and change the course of rotator cuff tear progression.7-12 CARTIHEAL◊ AGILI-C◊ Cartilage Repair Implant: Derived from a naturally occurring calcium carbonate known as aragonite, the CARTIHEAL Implant is a biphasic scaffold for cartilage repair and subchondral bone restoration.13-15 Shown to deliver clinically meaningful post-operative improvements in pain, function and quality of life,* the CARTIHEAL Implant is the only device approved for the treatment of knee cartilage and osteochondral defects in patients with or without mild to moderate osteoarthritis (KL 0-3).13,16 Q-FIX◊ KNOTLESS All-Suture Anchor: Building on the long-standing success and performance of the Q-FIX Family for best-in-class anchor fixation strength,**,17-21 the new Q-FIX KNOTLESS All-Suture Anchor raises the bar for all-suture anchor technology. With proprietary features and capabilities, the Q-FIX KNOTLESS All-Suture Anchor aims to set a new benchmark for soft tissue security†,22 and offer surgeons a new option for soft tissue-to-bone fixation indications across multiple joint spaces. 'Our inaugural turn sponsoring select players during The Championships, Wimbledon in 2024 was a tremendous success supporting athletes from across the globe – including Jasmine Paolini all the way to the Ladies Final,' said Christie van Geffen, SVP Global Sports Medicine Marketing for Smith+Nephew. 'We were able to uniquely feature the Smith+Nephew brand along with our leading Sports Medicine technology portfolio – designed to help weekend warriors and world-class athletes get back to competing and doing what they love.' If you would like to learn more about Smith+Nephew's leading Sports Medicine technology portfolio – including the CARTIHEAL AGILI-C Cartilage Repair Implant, the REGENETEN Bioinductive Implant and the Q-FIX KNOTLESS All-Suture Anchor – please visit here. – ends – Media Enquiries Dave Snyder +1 (978) 749-1440 Smith+Nephew [email protected] *Over a 2 and 4 year follow up **As compared to competitive devices in fixation/pull-out benchtop testing †As compared to the competitive device in cyclic benchtop testing References Smith+Nephew. Internal Data. Ruiz Ibán MÁ, García Navlet M, Moros Marco S, et al. Augmentation of a Transosseous-Equivalent Repair in Posterosuperior Nonacute Rotator Cuff Tears With a Bioinductive Collagen Implant Decreases the Retear Rate at One Year: A Randomized Controlled Trial. Arthroscopy: The Journal of Arthroscopic & Related Surgery. 2023:1-14. Bushnell BD, Connor PM, Harris HW, et al. Retear rates and clinical outcomes at 1 year after repair of full-thickness rotator cuff tears augmented with a bioinductive collagen implant: a prospective multicenter study. JSES international. 2021;5(2):228. Hein J, Reilly JM, Chae J, Maerz T, Anderson K. Retear Rates After Arthroscopic Single-Row, Double Row, and Suture Bridge Rotator Cuff Repair at a Minimum of 1 Year of Imaging Follow-up: A Systematic Review. Arthroscopy. 2015;31(11):2274-2281. Camacho-Chacon JA, Cuenca-Espierrez J, Roda-Rojo V, et al. Bioinductive collagen implants facilitate tendon regeneration in rotator cuff tears. J Exp Orthop. 2022;9(1):53. Smith + Nephew overview of the outcomes associated with the standard of care for the surgical treatment of rotator cuff tears. Internal Report EO/SPM/REGENETEN/005/v1. Bokor DJ, Sonnabend D, Deady L, et al. Evidence of healing of partial-thickness rotator cuff tears following arthroscopic augmentation with a collagen implant: a 2-year MRI follow-up. Muscles, Ligaments Tendons J. 2016;6(1):16-25. Schlegel TF, Abrams JS, Bushnell BD, Brock JL, Ho CP. Radiologic and clinical evaluation of a bioabsorbable collagen implant to treat partial-thickness tears: a prospective multicenter study. J Shoulder Elbow Surg. 2018 27(2):242-251. Van Kampen C, Arnoczky S, Parks P, et al. Tissue-engineered augmentation of a rotator cuff tendon using a reconstituted collagen scaffold: a histological evaluation in sheep. Muscles Ligaments Tendons J. 2013;3(3):229-235. Arnoczky SP, Bishai SK, Schofield B, et al. Histologic Evaluation of Biopsy Specimens Obtained After Rotator Cuff Repair Augmented With a Highly Porous Collagen Implant. Arthroscopy. 2017;33(2):278-283 Bokor DJ, Sonnabend DH, Deady L, et al. Healing of partial-thickness rotator cuff tears following arthroscopic augmentation with a highly porous collagen implant: a 5-year clinical and MRI follow-up. Muscles, Ligaments Tendons J. 2019;9(3):338-347. McElvany MD, McGoldrick E, Gee AO, Neradilek MB, Matsen FA, 3rd. Rotator cuff repair: published evidence on factors associated with repair integrity and clinical outcome. Am J Sports Med. 2015;43(2):491-500. Altschuler N, Zaslav KR, Di Matteo B, et al. Aragonite-Based Scaffold Versus Microfracture and Debridement for the Treatment of Knee Chondral and Osteochondral Lesions: Results of a Multicenter Randomized Controlled Trial. Am J Sports Med. 2023;51(4):957-967. doi:10.1177/03635465231151252 Kon E, Di Matteo B, Verdonk P, et al. Aragonite-Based Scaffold for the Treatment of Joint Surface Lesions in Mild to Moderate Osteoarthritic Knees: Results of a 2-Year Multicenter Prospective Study. Am J Sports Med. 2021;49(3):588-598. Kon E, Filardo G, Shani J, et al. Osteochondral regeneration with a novel aragonite-hyaluronate biphasic scaffold: up to 12-month follow-up study in a goat model. J Orthop Surg Res. 2015;10:81. Conte P, Anzillotti G, Crawford DC, et al. Differential analysis of the impact of lesions' location on clinical and radiological outcomes after the implantation of a novel aragonite-based scaffold to treat knee cartilage defects. Int Orthop. 2024;48(12):3117-3126 Douglass NP, et al. Arthroscopy. 2017;33(5):977-985 e975. Ergun S, et al. Arthroscopy. 2020; 2(3):e263-e275. Smith+Nephew 2023. Internal Report. 10090792- Revision B. ArthroCare Corporation 2017. Internal Report. P/N 49190-03 Rev. B. Smith+Nephew 2024. Internal Report. 10144423 Rev B. Smith and Nephew 10144423 Rev B About Smith+Nephew Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 17,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of $5.8 billion in 2024. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise. For more information about Smith+Nephew, please visit and follow us on X, LinkedIn, Instagram or Facebook. Forward-looking Statements This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as 'aim', 'plan', 'intend', 'anticipate', 'well-placed', 'believe', 'estimate', 'expect', 'target', 'consider' and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC's website at www. for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations. ◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Ottawa Citizen
14-05-2025
- Health
- Ottawa Citizen
A comparative sNPWT study of 10,000+ C-sections shows PICO™ sNPWT reduces complications and cuts healthcare costs by $728,000 per 1,000 patients
Article content Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces findings from a newly published comparative study of single-use Negative Pressure Wound Therapy (sNPWT) devices in Caesarean section (C-section) recovery has identified significant benefits for postpartum use of Smith+Nephew's leading PICO sNPWT technology. Analyzing real-world data from over 10,000 C-section patients treated at different pressure levels, the study published in WOUNDS (April 2025) reveals that PICO sNPWT contributes to a significant reduction in surgical site complications (SSCs), including a reduction in the incidence of surgical site infections (SSIs), wound dehiscence and seroma, and overall costs, compared to another sNPWT device (P≤0.05). 1 Article content Article content Article content New survey: The real-life burden of C-section complications A complementary survey of new mothers who have undergone C-sections highlighted the impact of SSCs on both mother and baby: 2 Article content Dr. Tia Welsh, M.D. Chair of Obstetrics and Gynecology at Valley Medical Group and co-author of the study added, ' Postpartum is already a very vulnerable period for mothers, even without complications. SSCs add physical pain, prolonged recoveries, emotional distress, and disrupt critical early bonding with newborns. These interruptions carry emotional and practical burdens, increasing the risks of postpartum depression, anxiety, and trauma – costs that can't be captured in dollars alone.' Article content Article content Real-world data shows the clinical and economic benefits of using PICO sNPWT in patients undergoing C-section procedures The study used real-world evidence from the Premier PINC AI™ Healthcare Database to analyze outcomes from a geographically diverse mix of community hospitals, teaching hospitals and healthcare systems across the US. Notable findings include significant reductions with PICO sNPWT, compared to other sNPWT devices in the incidence of*: Article content Overall SSIs (p=0.018) Superficial SSIs (p=0.017) Wound dehiscence (p=0.005) Seroma formation(p=0.050) Article content 'We've long understood the benefits of NPWT in surgical recovery, but this is the first large-scale study to directly compare different pressure levels in a real-world setting,' said Dr. Annmarie Vilkins, DO. Director of Obstetrics and Gynaecology at Henry Ford Health, and the study's lead author. 'We found that PICO sNPWT showed significantly improved outcomes through optimizing pressure, fluid management, and skin adhesion. Its unique design helped maintain a high moisture vapor transmission rate supporting an ideal healing environment for recovery, particularly critical for high-risk incisions like C-sections under skin folds, where moisture buildup can lead to infection.'
Hamilton Spectator
07-05-2025
- Health
- Hamilton Spectator
Study shows patients treated with Smith+Nephew's CARTIHEAL™ AGILI-C™ Cartilage Repair Implant have an 87% lower relative risk of Total Knee Arthroplasty or Osteotomy at 4 years¹*
The CARTIHEAL Implant will be featured at the Arthroscopy Association of North America Annual Meeting (AANA 2025) this week Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces encouraging results for its CARTIHEAL AGILI-C Cartilage Repair Implant from a recent multicentre randomised controlled trial (RCT) treating knee cartilage defects. When compared to the current surgical standard of care,* the implant demonstrated: Smith+Nephew's FDA-approved CARTIHEAL Implant, which previously received breakthrough designation, is revolutionizing the cartilage repair landscape. In line with AANA's mission to improve patient outcomes through education and innovation, the implant's broad indication allows physicians to treat patients who previously may not have had access. Professor Elizaveta Kon from Humanitas Research Hospital, who plans to present 4-year outcomes of the implant with respect to gender during AANA 2025, highlighted the importance of inclusivity in study design. 'We need a technology that we can trust to work in the patients we see day-to-day. This is where CARTIHEAL has excelled, showcasing superior performance across genders, lesion location, and more.' Dr. Vinod Dasa of Louisiana State University School of Medicine finds the technology particularly meaningful for his patients. 'The patients that come to see me are looking for a bridging procedure that enables them to continue their day-to-day life, playing with their kids and grandkids. In addition to the pain relief and functional gains, the 87% reduction in the risk of subsequent total knee arthroplasty (TKA) and osteotomy compared to the surgical standard of care resonates with almost every patient. The potential to delay if not avoid TKA is top of mind of almost every patient with mild/moderate osteoarthritis.' Using the CARTIHEAL Implant to treat a spectrum of cartilage pathologies will be featured during a lunch symposium on Friday, May 9 during AANA 2025. You can also learn more by visiting the CARTIHEAL Implant webpage here. To learn more about Smith+Nephew's Sports Medicine joint repair solutions and enabling technologies, please visit our booth (#303) at AANA 2025 in Washington DC May 8-10, or visit . - ends – Media Enquiries Dave Snyder +1 (978) 749-1440 Smith+Nephew * compared to debridement or microfracture ** over a 2- and 4-year follow-up References About Smith+Nephew Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 17,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of $5.8 billion in 2024. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise. For more information about Smith+Nephew, please visit and follow us on X , LinkedIn , Instagram or Facebook . Forward-looking Statements This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as 'aim', 'plan', 'intend', 'anticipate', 'well-placed', 'believe', 'estimate', 'expect', 'target', 'consider' and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC's website at www. , for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations. ◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.
